Thought Leadership
The Challenges of FDA's Nascent Biosimilars Regime
November 17, 2010
Chad A. Landmon
Law360

Axinn partner Chad Landmon's article, "The Challenges of FDA's Nascent Biosimilars Regime" was published by Law360.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.